多囊卵巢综合征与骨质疏松症既是女性内分泌疾病,且两者之间又存在错综复杂的联系。多囊卵巢综合征的特征是雄激素水平升高、胰岛素抵抗和体重增加,历来被认为可以预防骨骼脆性疾病。然而,新兴研究表明,在多囊卵巢综合征中普遍存在的慢性炎症会对骨骼健康产生不利影响。研究表明,多囊卵巢综合征患者的骨密度损失各不相同,其中胰岛素失衡、雄激素及生长激素异常、氧化应激、慢性炎症等关键因素,在PCOS和骨质疏松症之间的复杂相互作用中起着关键作用,影响骨代谢机制,从而导致骨质疏松症。这种错综复杂的骨代谢影响机制,强调了更深入地了解它们相互关系的必要性。因此,本综述阐明了PCOS与骨质疏松症之间的多方面激素水平、炎症及氧化应激反应的联系,强调了它们对PCOS患者骨骼健康管理的影响。Polycystic ovary syndrome (PCOS) and osteoporosis are both endocrine diseases of women, and there is a complex relationship between them. PCOS is characterized by elevated androgen levels, insulin resistance and weight gain and has historically been thought to protect against the brittle bone disease. However, emerging research suggests that chronic inflammation, which is prevalent in PCOS, can adversely affect bone health. Studies have shown that the bone mineral density loss in patients with PCOS varies, and key factors such as insulin imbalance, androgen and growth hormone abnormalities, oxidative stress, and chronic inflammation play a key role in the complex interaction between PCOS and osteoporosis, affecting the bone metabolism mechanism, leading to osteoporosis. This intricate mechanism of influence on bone metabolism underscores the need for a deeper understanding of their interrelationships. Therefore, this review elucidated the association of multiple hormone levels, inflammation, and oxidative stress responses between PCOS and osteoporosis, highlighting their impact on bone
骨形态发生ⅠA型受体(bone morphogenetic protein receptorⅠA,BMPRⅠA)在骨代谢疾病中发挥关键作用。BMP受体与转化生长因子β(TGF-β)配体结合传递信号,介导成骨细胞性骨形成与破骨细胞性骨吸收,参与骨发育、重塑等骨代谢过程。中药在防治骨代谢疾病方面历史悠久,对骨量、骨质量的促进作用显著。本文综述了BMPRⅠA与骨代谢疾病的作用机制,总结干预BMPRⅠA及其信号通路调节骨代谢的中药研究现状,以期为后续的药物研究提供思路。
